Actually, that is not true. As a matter of fact BP have funded many a trials for smaller companies based on the pre-clinical data. If a BP likes what the treatment suggests and the company has proved that they have been on the ball with their own DD, BP will fund trials from the onset with further funding being contingent upon performance.

BP have enough scientists and doctors on staff, all over the world, in every corner, that can look closely at a prospect and deem whether or not it is worth the risk. The doctors at Regen have done a marvelous job of showing that all that they are working on have very much earned the consideration of any BP.

Further, given the relationship between the doctors at Regen & ENTB, I don't think selling the company would be a consideration.

BMSN!